ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1

Completed

Conditions: Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions: Drug: decitabine
Biological: NY-ESO-1 peptide vaccine
Drug: pegylated liposomal doxorubicin hydrochloride
Biological: sargramostim
Biological: incomplete Freund's adjuvant
Other: immunohistochemistry staining method
Other: liquid chromatography
Other: mass spectrometry
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis
Genetic: DNA methylation analysis
Other: enzyme-linked immunosorbent assay

First Posted Date: 2012-08-27

Last Posted Date: 2022-08-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01673217

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy in Treating Patients With Lung Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Lung
Stage 0 Non-small Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Drug: HPPH
Drug: photodynamic therapy
Procedure: therapeutic bronchoscopy

First Posted Date: 2012-08-20

Last Posted Date: 2014-07-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 17

Registration Number: NCT01668823

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Not Applicable

Terminated

Conditions: Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage 0 Chronic Lymphocytic Leukemia

Interventions: Drug: lenalidomide
Other: laboratory biomarker analysis
Procedure: lymph node biopsy
Procedure: bone marrow aspiration
Other: pharmacological study
Other: flow cytometry

First Posted Date: 2012-07-25

Last Posted Date: 2016-06-30

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01649791

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery

Not Applicable

Completed

Conditions: Malignant Female Reproductive System Neoplasm

Interventions: Procedure: Infection Prophylaxis and Management

First Posted Date: 2012-05-14

Last Posted Date: 2020-07-23

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 435

Registration Number: NCT01597804

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Phase 1

Terminated

Conditions: Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: panobinostat
Drug: everolimus
Other: laboratory biomarker analysis
Other: pharmacological study
Other: liquid chromatography
Other: mass spectrometry
Other: enzyme-linked immunosorbent assay
Other: immunohistochemistry staining method

First Posted Date: 2012-04-20

Last Posted Date: 2022-08-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01582009

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Smac mimetic TL32711
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: biopsy

First Posted Date: 2012-04-10

Last Posted Date: 2022-08-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01573780

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Contiguous Stage II Adult Burkitt Lymphoma
de Novo Myelodysplastic Syndromes
Recurrent Adult Burkitt Lymphoma
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Previously Treated Myelodysplastic Syndromes
Stage III Adult Burkitt Lymphoma

Interventions: Drug: rasburicase
Drug: allopurinol

First Posted Date: 2012-03-27

Last Posted Date: 2018-01-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01564277

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Not Applicable

Terminated

Conditions: Healthy, no Evidence of Disease

Interventions: Dietary Supplement: cholecalciferol
Other: questionnaire administration
Biological: trivalent influenza vaccine

First Posted Date: 2012-03-23

Last Posted Date: 2020-03-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01561989

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Not Applicable

Withdrawn

Conditions: Adult Acute Myeloid Leukemia in Remission
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Adult Burkitt Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Procedure: management of therapy complications
Procedure: musculoskeletal complications management/prevention

First Posted Date: 2012-03-20

Last Posted Date: 2012-07-09

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01558778

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Biological: trebananib
Other: laboratory biomarker analysis
Drug: cytarabine
Other: pharmacological study

First Posted Date: 2012-03-15

Last Posted Date: 2022-09-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01555268

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States

AI-Powered Research

Premium Access

ROSWELL PARK CANCER INSTITUTE

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Photodynamic Therapy in Treating Patients With Lung Cancer

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia